Peter Greenleaf
2016 - Sucampo Pharmaceuticals
In 2016, Peter Greenleaf earned a total compensation of $4.3M as Chief Executive Officer and Chairman of the Board of Directors at Sucampo Pharmaceuticals, a 38% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $615,513 |
|---|---|
| Option Awards | $3,061,590 |
| Salary | $652,991 |
| Other | $9,000 |
| Total | $4,339,094 |
Greenleaf received $3.1M in option awards, accounting for 71% of the total pay in 2016.
Greenleaf also received $615.5K in non-equity incentive plan, $653K in salary and $9K in other compensation.
Rankings
In 2016, Peter Greenleaf's compensation ranked 1,979th out of 14,075 executives tracked by ExecPay. In other words, Greenleaf earned more than 85.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,979 out of 14,075 | 86th |
Division Manufacturing | 678 out of 5,486 | 88th |
Major group Chemicals And Allied Products | 191 out of 1,900 | 90th |
Industry group Drugs | 136 out of 1,543 | 91st |
Industry Pharmaceutical Preparations | 109 out of 1,173 | 91st |
Source: SEC filing on April 21, 2017.
Greenleaf's colleagues
We found four more compensation records of executives who worked with Peter Greenleaf at Sucampo Pharmaceuticals in 2016.
2016
Peter Kiener
Sucampo Pharmaceuticals
Chief Scientific Officer
2016
Max Donley
Sucampo Pharmaceuticals
EVP, Global Human Resources, Information Technology and Strategy
2016
Matthias Alder
Sucampo Pharmaceuticals
General Counsel
2016
Andrew Smith
Sucampo Pharmaceuticals
Chief Financial Officer
News
Aurinia Pharmaceuticals CEO Peter Greenleaf's 2021 pay falls 88% to $1.2M
April 18, 2022
Aurinia Pharmaceuticals CEO Peter Greenleaf's 2020 pay jumps 1,353% to $11M
May 10, 2021
Avalo Therapeutics Chairman Simon Pedder's 2019 pay jumps 13,562% to $3.8M
April 28, 2020
Avalo Therapeutics CEO Peter Greenleaf's 2018 pay jumps 17,372% to $5.1M
June 19, 2019